Noncanonical effects of IRF9 in intestinal inflammation: More than type I and type III interferons

Molecular and Cellular Biology

Volumn 35, Issue 13, 2015, Pages 2332-2343

  Rauch, Isabella ^a,d   Rosebrock, Felix ^a   Hainzl, Eva ^c   Heider, Susanne ^b   Majoros, Andrea ^a   Wienerroither, Sebastian ^a   Strobl, Birgit ^c   Stockinger, Silvia ^c   Kenner, Lukas ^b   Müller, Mathias ^c   Decker, Thomas ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CXCL2 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON RECEPTOR; INTERFERON REGULATORY FACTOR 7; INTERFERON REGULATORY FACTOR 9; INTERFERON STIMULATED GENE FACTOR 15; INTERFERON STIMULATED GENE FACTOR 3; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 28 RECEPTOR ALPHA; MESSENGER RNA; STAT1 PROTEIN; STAT2 PROTEIN; UNCLASSIFIED DRUG; DEXTRAN SULFATE; INTERFERON; IRF9 PROTEIN, MOUSE; STAT1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BONE MARROW DERIVED MACROPHAGE; COMPLEX FORMATION; CONTROLLED STUDY; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; GENE CONTROL; GENE EXPRESSION; GENOTYPE; INTESTINE EPITHELIUM CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED; COLITIS; COLON; GENE DELETION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MALE; PATHOLOGY;

ANIMALIA; MURINAE;

ANIMALS; CELLS, CULTURED; CHEMOKINE CXCL10; COLITIS; COLON; DEXTRAN SULFATE; GENE DELETION; GENE EXPRESSION REGULATION; INTERFERON-STIMULATED GENE FACTOR 3, GAMMA SUBUNIT; INTERFERONS; MALE; MICE, INBRED BALB C; MICE, INBRED C57BL; PROMOTER REGIONS, GENETIC; RECEPTORS, INTERFERON; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR;

EID: 84930838366     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01498-14     Document Type: Article

References (51)

1. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR. 2007. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 6:975-990. http://dx.doi.org/10.1038/nrd2422.
2. Donnelly RP, Kotenko SV. 2010. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res 30:555-564. http://dx.doi.org/10.1089/jir.2010.0078.
3. Rauch I, Müller M, Decker T. 2013. The regulation of inflammation by interferons and their STATs. JAKSTAT 2:e23820. http://dx.doi.org/10.4161/jkst.23820.
4. Moschella F, Torelli GF, Valentini M, Urbani F, Buccione C, Petrucci MT, Natalino F, Belardelli F, Foà R, Proietti E. 2013. Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients' blood cells: implications for cancer chemoimmunotherapy. Clin Cancer Res 19:4249-4261. http://dx.doi.org/10.1158/1078-0432.CCR-12-3666.
5. González-Navajas JM, Lee J, David M, Raz E. 2012. Immunomodulatory functions of type I interferons. Nat Rev Immunol 12:125-135. http://dx.doi.org/10.1038/nri3133.
6. Levy DE, Darnell JEJ. 2002. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3:651-662. http://dx.doi.org/10.1038/nrm909.
7. Fink K, Grandvaux N. 2013. STAT2 and IRF9: beyond ISGF3. JAKSTAT 2:e27521. http://dx.doi.org/10.4161/jkst.27521.
8. Majumder S, Zhou LZ, Chaturvedi P, Babcock G, Aras S, Ransohoff RM. 1998. p48/STAT-1alpha-containing complexes play a predominant role in induction of IFN-gamma-inducible protein, 10 kDa (IP-10) by IFN-gamma alone or in synergy with TNF-alpha. J Immunol 161:4736-4744.
9. Perry ST, Buck MD, Lada SM, Schindler C, Shresta S. 2011. STAT2 mediates innate immunity to Dengue virus in the absence of STAT1 via the type I interferon receptor. PLoS Pathog 7:e1001297. http://dx.doi.org/10.1371/journal.ppat.1001297.
10. Morrow AN, Schmeisser H, Tsuno T, Zoon KC. 2011. A novel role for IFN-stimulated gene factor 3II in IFN-γ signaling and induction of antiviral activity in human cells. J Immunol 186:1685-1693. http://dx.doi.org/10.4049/jimmunol.1001359.
11. Fink K, Martin L, Mukawera E, Chartier S, De Deken X, Brochiero E, Miot F, Grandvaux N. 2013. IFN-ß/TNFα synergism induces a noncanonical STAT2/IRF9-dependent pathway triggering a novel DUOX2 NADPH Oxidase-mediated airway antiviral response. Cell Res 23:673-690. http://dx.doi.org/10.1038/cr.2013.47.
12. Farlik M, Rapp B, Marie I, Levy DE, Jamieson AM, Decker T. 2012. Contribution of a TANK-binding kinase 1-interferon (IFN) regulatory factor 7 pathway to IFN-γ-induced gene expression. Mol Cell Biol 32:1032-1043. http://dx.doi.org/10.1128/MCB.06021-11.
13. Sommereyns C, Paul S, Staeheli P, Michiels T. 2008. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 4:e1000017. http://dx.doi.org/10.1371/journal.ppat.1000017.
14. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R. 2007. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol 81:7749-7758. http://dx.doi.org/10.1128/JVI.02438-06.
15. Levy DE, Marié IJ, Durbin JE. 2011. Induction and function of type I and III interferon in response to viral infection. Curr Opin Virol 1:476-486. http://dx.doi.org/10.1016/j.coviro.2011.11.001.
16. Maloy KJ, Powrie F. 2011. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 474:298-306. http://dx.doi.org/10.1038/nature10208.
17. Sekirov I, Champion OL, Gaynor EC, Finlay BB. 2007. Host-mediated inflammation disrupts the intestinal microbiota and promotes the over-growth of Enterobacteriaceae. Cell Host Microbe 2:119-129. http://dx.doi.org/10.1016/j.chom.2007.06.010.
18. Berry D, Schwab C, Milinovich G, Reichert J, Ben Mahfoudh K, Decker T, Engel M, Hai B, Hainzl E, Heider S, Kenner L, Muller M, Rauch I, Strobl B, Wagner M, Schleper C, Urich T, Loy A. 2012. Phylotype-level 16S rRNA analysis reveals new bacterial indicators of health state in acute murine colitis. ISME J 6:2091-2106. http://dx.doi.org/10.1038/ismej.2012.39.
19. Rauch I, Hainzl E, Rosebrock F, Heider S, Schwab C, Berry D, Stoiber D, Wagner M, Schleper C, Loy A, Urich T, Müller M, Strobl B, Kenner L, Decker T. 2014. Type I interferons have opposing effects during the emergence and recovery phases of colitis. Eur J Immunol 44:2749-2760. http://dx.doi.org/10.1002/eji.201344401.
20. Salk A, Stobaugh DJ, Deepak P, Ehrenpreis ED. 2013. Ischemic colitis with type I interferons used in the treatment of hepatitis C and multiple sclerosis: an evaluation from the food and drug administration adverse event reporting system and review of the literature. Ann Pharmacother 47:537-542. http://dx.doi.org/10.1345/aph.1R526.
21. Jin Y, Lin Y, Lin L, Zheng C. 2012. IL-17/IFN-γ interactions regulate intestinal inflammation in TNBS-induced acute colitis. J Interferon Cytokine Res 32:548-556. http://dx.doi.org/10.1089/jir.2012.0030.
22. Sheikh SZ, Matsuoka K, Kobayashi T, Li F, Rubinas T, Plevy SE. 2010. Cutting edge: IFN-ß is a negative regulator of IL-23 in murine macrophages and experimental colitis. J Immunol 184:4069-4073. http://dx.doi.org/10.4049/jimmunol.0903600.
23. Nava P, Koch S, Laukoetter MG, Lee WY, Kolegraff K, Capaldo CT, Beeman N, Addis C, Gerner-Smidt K, Neumaier I, Skerra A, Li L, Parkos CA, Nusrat A. 2010. Interferon-gamma regulates intestinal epithelial homeostasis through converging beta-catenin signaling pathways. Immunity 32:392-402. http://dx.doi.org/10.1016/j.immuni.2010.03.001.
24. Ito R, Shin-Ya M, Kishida T, Urano A, Takada R, Sakagami J, Imanishi J, Kita M, Ueda Y, Iwakura Y, Kataoka K, Okanoue T, Mazda O. 2006. Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin Exp Immunol 146:330-338. http://dx.doi.org/10.1111/j.1365-2249.2006.03214.x.
25. Obermeier F, Kojouharoff G, Hans W, Scholmerich J, Gross V, Falk W. 1999. Interferon-gamma (IFN-γ)-and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice. Clin Exp Immunol 116:238-245. http://dx.doi.org/10.1046/j.1365-2249.1999.00878.x.
26. Hans W, Scholmerich J, Gross V, Falk W. 2000. Interleukin-12 induced interferon-gamma increases inflammation in acute dextran sulfate sodium induced colitis in mice. Eur Cytokine Netw 11:67-74.
27. Pott J, Mahlakõiv T, Mordstein M, Duerr CU, Michiels T, Stockinger S, Staeheli P, Hornef MW. 2011. IFN-λ determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci U S A 108:7944-7949. http://dx.doi.org/10.1073/pnas.1100552108.
28. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte J-M, Diebold J, Diepolder H, Adler B, Auernhammer CJ, Göke B, Dambacher J. 2005. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol 289:G960-G968. http://dx.doi.org/10.1152/ajpgi.00126.2005.
29. Bierne H, Travier L, Mahlakoiv T, Tailleux L, Subtil A, Lebreton A, Paliwal A, Gicquel B, Staeheli P, Lecuit M, Cossart P. 2012. Activation of type III interferon genes by pathogenic bacteria in infected epithelial cells and mouse placenta. PLoS One 7:e39080. http://dx.doi.org/10.1371/journal.pone.0039080.
30. Mordstein M, Kochs G, Dumoutier L, Renauld J-C, Paludan SR, Klucher K, Staeheli P. 2008. Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog 4:e1000151. http://dx.doi.org/10.1371/journal.ppat.1000151.
31. Horisberger MA, Staeheli P, Haller O. 1983. Interferon induces a unique protein in mouse cells bearing a gene for resistance to influenza virus. Proc Natl Acad Sci U S A 80:1910-1914. http://dx.doi.org/10.1073/pnas.80.7.1910.
32. Kimura T, Kadokawa Y, Harada H, Matsumoto M, Sato M, Kashiwazaki Y, Tarutani M, Tan RS, Takasugi T, Matsuyama T, Mak TW, Noguchi S, Taniguchi T. 1996. Essential and non-redundant roles of p48 (ISGF3 gamma) and IRF-1 in both type I and type II interferon responses, as revealed by gene targeting studies. Genes Cells 1:115-124. http://dx.doi.org/10.1046/j.1365-2443.1996.08008.x.
33. Durbin JE, Hackenmiller R, Simon MC, Levy DE. 1996. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84:443-450. http://dx.doi.org/10.1016/S0092-8674(00)81289-1.
34. Park C, Li S, Cha E, Schindler C. 2000. Immune response in Stat2 knockout mice. Immunity 13:795-804. http://dx.doi.org/10.1016/S1074-7613(00)00077-7.
35. Williams KL, Fuller CR, Dieleman LA, DaCosta CM, Haldeman KM, Sartor RB, Lund PK. 2001. Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone. Gastroenterology 120:925-937. http://dx.doi.org/10.1053/gast.2001.22470.
36. Stockinger S, Reutterer B, Schaljo B, Schellack C, Brunner S, Materna T, Yamamoto M, Akira S, Taniguchi T, Murray PJ, Muller M, Decker T. 2004. IFN regulatory factor 3-dependent induction of type I IFNs by intracellular bacteria is mediated by a TLR- and Nod2-independent mechanism. J Immunol 173:7416-7425. http://dx.doi.org/10.4049/jimmunol.173.12.7416.
37. Wienerroither S, Rauch I, Rosebrock F, Jamieson AM, Bradner J, Muhar M, Zuber J, Müller M, Decker T. 2014. Regulation of NO synthesis, local inflammation, and innate immunity to pathogens by BET family proteins. Mol Cell Biol 34:415-427. http://dx.doi.org/10.1128/MCB.01353-13.
38. Rogers GB, Kozlowska J, Keeble J, Metcalfe K, Fao M, Dowd SE, Mason AJ, McGuckin MA, Bruce KD. 2014. Functional divergence in gastrointestinal microbiota in physically separated genetically identical mice. Sci Rep 4:5437. http://dx.doi.org/10.1038/srep05437.
39. Gough DJ, Messina NL, Clarke CJP, Johnstone RW, Levy DE. 2012. Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity 36:166-174. http://dx.doi.org/10.1016/j.immuni.2012.01.011.
40. Groom JR, Luster AD. 2011. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 89:207-215. http://dx.doi.org/10.1038/icb.2010.158.
41. Ohmori Y, Hamilton TA. 1993. Cooperative interaction between interferon (IFN) stimulus response element and kappa B sequence motifs controls IFN gamma- and lipopolysaccharide-stimulated transcription from the murine IP-10 promoter. J Biol Chem 268:6677-6688.
42. Begitt A, Droescher M, Meyer T, Schmid CD, Baker M, Antunes F, Owen MR, Naumann R, Decker T, Vinkemeier U. 2014. STAT1-cooperative DNA binding distinguishes type 1 from type 2 interferon signaling. Nat Immunol 15:168-176. http://dx.doi.org/10.1038/ni.2794.
43. Hyun JG, Lee G, Brown JB, Grimm GR, Tang Y, Mittal N, Dirisina R, Zhang Z, Fryer JP, Weinstock JV, Luster AD, Barrett TA. 2005. Antiinterferon-inducible chemokine, CXCL10, reduces colitis by impairing T helper-1 induction and recruitment in mice. Inflamm Bowel Diseases 11:799-805. http://dx.doi.org/10.1097/01.MIB.0000178263.34099.89.
44. Singh UP, Singh S, Singh R, Cong Y, Taub DD, Lillard JW. 2008. CXCL10-producing mucosal CD4+ T cells, NK cells, and NKT cells are associated with chronic colitis in IL-10(-/-) mice, which can be abrogated by anti-CXCL10 antibody inhibition. J Interferon Cytokine Res 28:31-43. http://dx.doi.org/10.1089/jir.2007.0059.
45. Singh UP, Singh S, Taub DD, Lillard JW. 2003. Inhibition of IFN-gamma-inducible protein-10 abrogates colitis in IL-10-/- mice. J Immunol 171:1401-1406. http://dx.doi.org/10.4049/jimmunol.171.3.1401.
46. Suzuki K, Kawauchi Y, Palaniyandi SS, Veeraveedu PT, Fujii M, Yamagiwa S, Yoneyama H, Han GD, Kawachi H, Okada Y, Ajioka Y, Watanabe K, Hosono M, Asakura H, Aoyagi Y, Narumi S. 2007. Blockade of interferon-gamma-inducible protein-10 attenuates chronic experimental colitis by blocking cellular trafficking and protecting intestinal epithelial cells. Pathol Int 57:413-420. http://dx.doi.org/10.1111/j.1440-1827.2007.02117.x.
47. Sasaki S, Yoneyama H, Suzuki K, Suriki H, Aiba T, Watanabe S, Kawauchi Y, Kawachi H, Shimizu F, Matsushima K, Asakura H, Narumi S. 2002. Blockade of CXCL10 protects mice from acute colitis and enhances crypt cell survival. Eur J Immunol 32:3197-3205. http://dx.doi.org/10.1002/1521-4141(200211)32:11<3197::AID-IMMU3197>3.0.CO;2-1.
48. Chami B, Yeung AWS, van Vreden C, King NJC, Bao S. 2014. The role of CXCR3 in DSS-induced colitis. PLoS One 9:e101622. http://dx.doi.org/10.1371/journal.pone.0101622.
49. Mayer L, Sandborn WJ, Stepanov Y, Geboes K, Hardi R, Yellin M, Tao X, Xu LA, Salter-Cid L, Gujrathi S, Aranda R, Luo AY. 2014. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut 63:442-450. http://dx.doi.org/10.1136/gutjnl-2012-303424.
50. Luster AD, Unkeless JC, Ravetch JV. 1985. Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 315:672-676. http://dx.doi.org/10.1038/315672a0.
51. Cheon H, Stark GR. 2009. Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc Natl Acad Sci U S A 106:9373-9378. http://dx.doi.org/10.1073/pnas.0903487106.